Citizens Reiterates Market Outperform on Mirum Pharmaceuticals, Maintains $137 Price Target
Mirum Pharmaceuticals
Mirum Pharmaceuticals MIRM | 0.00 |
Citizens analyst Jonathan Wolleben reiterates Mirum Pharmaceuticals (NASDAQ:
MIRM) with a Market Outperform and maintains $137 price target.
